🍽️ thiethylperazine dimalate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antiemetic Effects: Thiethylperazine dimaleate is classified as an antiemetic, which means it helps prevent or relieve nausea and vomiting. It works by blocking dopamine receptors in the chemoreceptor trigger zone (CTZ) of the brain, thereby reducing the signals that trigger vomiting.

  2. Indications: Torecan is typically prescribed for the management of nausea and vomiting caused by various factors, including:

    • Motion sickness
    • Postoperative nausea and vomiting (PONV)
    • Nausea and vomiting associated with chemotherapy or radiation therapy
    • Gastrointestinal disorders such as gastroenteritis or peptic ulcer disease
    • Migraine-associated nausea and vomiting
  3. Dosage and Administration: The dosage of Torecan varies depending on the individual's age, weight, and the severity of symptoms. It is usually taken orally as tablets or administered intramuscularly or intravenously in more severe cases. The medication should be taken as directed by a healthcare professional.

  4. Onset and Duration of Action: Torecan typically begins to take effect within 30 to 60 minutes after oral administration. The duration of its antiemetic effects can last for several hours, but the exact duration varies among individuals.

  5. Side Effects: Common side effects of thiethylperazine dimaleate may include:

    • Drowsiness or sedation
    • Dizziness
    • Dry mouth
    • Blurred vision
    • Constipation
    • Urinary retention
    • Changes in appetite
    • Skin rash or allergic reactions
  6. Precautions: Torecan should be used with caution in individuals who are sensitive to antihistamines or have a history of certain medical conditions, such as glaucoma, urinary retention, or prostatic hypertrophy. It may also impair cognitive and motor functions, so patients should avoid activities requiring mental alertness, such as driving or operating machinery, while taking this medication.

  7. Drug Interactions: Thiethylperazine dimaleate may interact with other medications, including central nervous system depressants such as alcohol, benzodiazepines, and opioids. Patients should inform their healthcare provider about all medications, supplements, or herbal products they are taking to prevent potential interactions.

  8. Contraindications: Torecan is contraindicated in individuals with a known hypersensitivity to the drug or its components. It should also be avoided in patients with severe central nervous system depression, coma, or liver disease.

  9. Pregnancy and Lactation: The safety of thiethylperazine dimaleate during pregnancy and lactation has not been established. Pregnant or breastfeeding women should consult their healthcare provider before using this medication.

  10. Overdose: In case of overdose, symptoms may include excessive sedation, respiratory depression, or cardiovascular effects. Immediate medical attention should be sought if an overdose is suspected.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of thiethylperazine dimalate,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium longum Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by thiethylperazine dimalate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Mediterraneibacter genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Bacteroides genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Clostridioides genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Akkermansia genus Decreases 📓 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Agathobacter rectalis species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Bilophila wadsworthia species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Roseburia hominis species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Enterocloster bolteae species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Allisonella histaminiformans species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Akkermansia glycaniphila species Decreases 👶 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of thiethylperazine dimalate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.5 0.5
Acne 0.1 -0.1
ADHD 2.5 0.5 4
Age-Related Macular Degeneration and Glaucoma 0.6 0.3 1
Allergic Rhinitis (Hay Fever) 1.5 0.2 6.5
Allergies 3.3 1.3 1.54
Allergy to milk products 0.3 0.3 0
Alopecia (Hair Loss) 1.8 1.8
Alzheimer's disease 2.6 6.1 -1.35
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.6 0.2 12
Ankylosing spondylitis 2.9 1.7 0.71
Anorexia Nervosa 0.3 2.1 -6
Antiphospholipid syndrome (APS) 1.5 0.5 2
Asthma 0.1 1 -9
Atherosclerosis 0.4 1.5 -2.75
Atrial fibrillation 2.7 2.1 0.29
Autism 6.3 8.1 -0.29
Biofilm 0.9 0.9
Bipolar Disorder 1.1 1 0.1
Brain Trauma 0.4 0.7 -0.75
Cancer (General) 0.2 -0.2
Carcinoma 2.1 1.6 0.31
Celiac Disease 1.3 2.4 -0.85
Cerebral Palsy 0.2 1.2 -5
Chronic Fatigue Syndrome 3.5 7.1 -1.03
Chronic Kidney Disease 1.5 2.7 -0.8
Chronic Lyme 0.7 -0.7
Chronic Obstructive Pulmonary Disease (COPD) 1.3 -1.3
Chronic Urticaria (Hives) 2 -2
Coagulation / Micro clot triggering bacteria 0.3 0.9 -2
Colorectal Cancer 1.9 0.9 1.11
Constipation 1.7 0.9 0.89
Coronary artery disease 1.8 0.9 1
COVID-19 5 10.7 -1.14
Crohn's Disease 5.7 5.6 0.02
cystic fibrosis 0.8 -0.8
deep vein thrombosis 0.5 -0.5
Depression 5.7 6.1 -0.07
Dermatomyositis 0.1 -0.1
Eczema 0.9 0.9 0
Endometriosis 1.7 0.4 3.25
Epilepsy 2 1.5 0.33
Fibromyalgia 1.4 3.3 -1.36
Functional constipation / chronic idiopathic constipation 4.1 3.1 0.32
gallstone disease (gsd) 0.9 0.5 0.8
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.8 0.9 1
Generalized anxiety disorder 1.4 1 0.4
Gout 0.5 -0.5
Graves' disease 1 1.3 -0.3
Halitosis 0.3 0.3
Hashimoto's thyroiditis 1.5 0.8 0.88
Hidradenitis Suppurativa 0.5 0.5
High Histamine/low DAO 0.4 0.1 3
hypercholesterolemia (High Cholesterol) 0.2 -0.2
hyperglycemia 0.1 1.4 -13
Hyperlipidemia (High Blood Fats) 0.5 0.3 0.67
hypersomnia 0.9 -0.9
hypertension (High Blood Pressure 1.1 4.5 -3.09
Hypothyroidism 1 -1
Hypoxia 0.7 0.7
IgA nephropathy (IgAN) 4.4 -4.4
Inflammatory Bowel Disease 2.4 8.6 -2.58
Insomnia 0.7 1.1 -0.57
Intelligence 1.5 1 0.5
Intracranial aneurysms 1 0.3 2.33
Irritable Bowel Syndrome 1.6 3.7 -1.31
Liver Cirrhosis 2.7 2 0.35
Long COVID 6.3 7 -0.11
Low bone mineral density 1.3 -1.3
Lung Cancer 0.8 -0.8
Mast Cell Issues / mastitis 0.6 -0.6
ME/CFS with IBS 0.5 2.5 -4
ME/CFS without IBS 1 1.7 -0.7
Menopause 0.2 0.2
Metabolic Syndrome 5.5 6.6 -0.2
Mood Disorders 7.2 6.1 0.18
multiple chemical sensitivity [MCS] 0.1 0.4 -3
Multiple Sclerosis 1.9 5.5 -1.89
Multiple system atrophy (MSA) 1 0.6 0.67
neuropathic pain 1.5 -1.5
Neuropathy (all types) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.9 4 -1.11
NonCeliac Gluten Sensitivity 0.1 -0.1
Obesity 5.7 2.4 1.38
obsessive-compulsive disorder 5.2 4.1 0.27
Osteoarthritis 1.2 0 0
Osteoporosis 0.3 0.9 -2
Parkinson's Disease 2 4.1 -1.05
Polycystic ovary syndrome 2 0.7 1.86
Postural orthostatic tachycardia syndrome 0.6 -0.6
Premenstrual dysphoric disorder 0.9 0.3 2
primary biliary cholangitis 0.1 1.3 -12
Psoriasis 2.4 3.6 -0.5
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 6.1 2.6 1.35
Rosacea 0.1 0.4 -3
Schizophrenia 3.7 1.5 1.47
scoliosis 0.5 1.3 -1.6
Sjögren syndrome 1.7 2.7 -0.59
Sleep Apnea 1.1 1.7 -0.55
Slow gastric motility / Gastroparesis 0.3 0.1 2
Small Intestinal Bacterial Overgrowth (SIBO) 0.2 -0.2
Stress / posttraumatic stress disorder 1.3 1.8 -0.38
Systemic Lupus Erythematosus 3.7 1.4 1.64
Tic Disorder 1 1.7 -0.7
Tourette syndrome 0.1 0.3 -2
Type 1 Diabetes 3.6 1.8 1
Type 2 Diabetes 6.4 5.8 0.1
Ulcerative colitis 1 5.3 -4.3
Unhealthy Ageing 4.9 2.1 1.33

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]